PEG-loxenatide
GLP-1 · s.c. weekly · Hansoh
Summary
- Also known as
- Hansoh (Fulaimei)
- Mechanism
- GLP-1
- Route
- s.c. weekly
- Company
- Hansoh
- Highest development stage
- approved
- Status (as of data cut)
- Approved in China for T2D (May 2019, Fulaimei) verify
- Next milestone
- —
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | Phase 3 registered on ClinicalTrials.gov | |
| T2D | 4 approved / in label | NMPA (China), May 2019 (Fulaimei) | Hansoh announcement |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PEX168 add-on to metformin phase 3b | 100 μg + metformin | t2d china | 24 | — | — | — | −1.2 | — | — | — | — | 0.0 vs 0.0 | — | press release |
| PEX168 add-on to metformin phase 3b | 200 μg + metformin | t2d china | 24 | — | — | — | −1.1 | — | — | — | — | 0.0 vs 0.0 | — | press release |
| PEX168 monotherapy phase 3a | 100 μg | t2d china | 24 | 361 | — | — | −1.0 vs −0.2 | 1.6 vs 0.8 | — | 5.6 vs 0.0 | 2.4 vs 0.0 | — | — | press release |
| PEX168 monotherapy phase 3a | 200 μg | t2d china | 24 | 361 | — | — | −1.3 vs −0.2 | 2.5 vs 0.8 | — | 10.0 vs 0.0 | 8.3 vs 0.0 | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (12)
- 100 μg · hba1c · publication
The HbA1c least-square mean (95% CI) change from baseline to week 24 was greater for PEX168/100 μg (-1.02% [-1.21%, -0.83%]) and PEX168/200 μg (-1.34% [-1.54%, -1.15%]) than for placebo (-0.17% [-0.36%, 0.02%])
- 100 μg · nausea · publication
nausea (5.6%, 10.0% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
- 100 μg · vomiting · publication
vomiting (2.4%, 8.3% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
- 100 μg · ae_dc · publication
(PEX168/100 μg: N = 2 [1.6%], PEX168/200 μg: N = 3 [2.5%] and placebo: N = 1 [0.8%]) discontinued treatment because of AEs
- 200 μg · hba1c · publication
The HbA1c least-square mean (95% CI) change from baseline to week 24 was greater for PEX168/100 μg (-1.02% [-1.21%, -0.83%]) and PEX168/200 μg (-1.34% [-1.54%, -1.15%]) than for placebo (-0.17% [-0.36%, 0.02%])
- 200 μg · nausea · publication
nausea (5.6%, 10.0% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
- 200 μg · vomiting · publication
vomiting (2.4%, 8.3% and 0% for PEX168/100 μg, PEX168/200 μg and placebo, respectively)
- 200 μg · ae_dc · publication
(PEX168/100 μg: N = 2 [1.6%], PEX168/200 μg: N = 3 [2.5%] and placebo: N = 1 [0.8%]) discontinued treatment because of AEs
- 100 μg + metformin · hba1c · publication
in the PEX168 groups (-1.16% [0.08%] and -1.14% [0.08%] with 100 and 200 μg, respectively)
- 100 μg + metformin · sae · Abstract, Results
No treatment-emergent serious adverse events occurred.
- 200 μg + metformin · hba1c · publication
in the PEX168 groups (-1.16% [0.08%] and -1.14% [0.08%] with 100 and 200 μg, respectively)
- 200 μg + metformin · sae · Abstract, Results
No treatment-emergent serious adverse events occurred.
Registered trials (1)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT05172999 Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia | Obesity | Phase 3 | completed | 2022-01 → 2025-12 | 30 | Completed; results not in the atlas yet | NCT05172999 |
Primary sources
- Shuai Y, Yang G, Zhang Q, Li W, Luo Y, Ma J, et al. Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial. Diabetes Obes Metab. 2021;23(1):116-124. PMID: 32965075.
- Gao F, Lv X, Mo Z, Ma J, Zhang Q, Yang G, et al. Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial. Diabetes Obes Metab. 2020;22(12):2375-2383. PMID: 32744358.
How to cite this page
Cite the primary publication for any single result; every value above links to it.